Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic

CompletedOBSERVATIONAL
Enrollment

1,400

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

October 17, 2021

Study Completion Date

December 13, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Inactivated COVID-19 Vaccine

Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen

Trial Locations (10)

Unknown

Gral Esp Ntra Sra dela Alt, Higuamo

Hospital IMG, Salvaleón de Higüey

Moscoso Puello Hospital, Bella Vista

Felix Maria Goico Hospital, Villa Francisca

Centro Médico Bournigal, Puerto Plata

Ricardo Limardo, Sosua, Cabarete

JoséM.Cabral V Báez, Puñal

Clinica Unión Medica del Norte, Santiago de los Caballeros

Marcelino Vélez Santana, Guerra

Fuerza AéreaDr Ramón Lara, Los Alcarrizos

All Listed Sponsors
lead

Sinovac Research and Development Co., Ltd.

INDUSTRY

NCT04974164 - Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic | Biotech Hunter | Biotech Hunter